S4 Fig. Evaluation of the activity of the non-peptide PKR1 agonists IS1 and IS20 in vitro. A. IS20 (100 nM) cannot increase ERK activity in the presence of PKR2 in CHO cells. However, prokineticin-2 (10nM) was able to activate ERK kinase via PKR2. B. IS20 acts as positive allosteric modulator by further increasing PK2 function on ERK activity. C. IS20 promotes Akt activity in a dose-dependent manner in CHO cells expressing PKR1 EC<sub>50</sub> 10nM). * p<0.05.